Background: Patient reported outcome measures are comprised of either sets of questionnaires or patient global assessment based on visual analogue scale (VAS). These patient-reported outcome measures lack accuracy and/or clinical feasibility when comparing heterogeneous patient groups with different diseases, or when characterizing patients with systemic disease involving different organ systems. Objectives: Developing a clinical feasible patient-reported outcome measure based VAS assessment of different organ systems. Methods: Patients were asked to rate their health status in a 10cm VAS (0-100%) concerning their global health as well as of different organ systems, namely heart, lung, muscle and joints, gastro-intestinal, metabolic, uro-genital, skin, neuro-psychiatric, eyes and ears. All VA-scales were "anchored". Patients were advised to rate their health status below 75% if they felt "medical action is needed", they should rate the health status <50% in case of a "strong need for medical action" and <25% in case of a "medical emergency". 336 patients from different outpatient clinics (cardiologic, pneumologic, gastrointestinal, nephrologic, neurologic, dermatologic, rheumatologic, ophthalmologic and obesity outpatient clinic) as well as patients from internal emergency clinics and a general practitioner clinic were evaluated. Both, patients and the attending physicians completed the Popgen-OSSA. In addition the attending physician was asked to document ranking of the 5 most important diagnoses of the patient. Statistical analysis was carried out using non-parametric testing. Furthermore, to predict main diagnoses based on patients's as well as physician's OSSA state-of-the-art machine learning tools, namely support vector machines (SVMs), were applied. To assess model performance multi-class AUC (area under the ROC curve) according to Hand and Till (2001) was estimated based on repeated cross validation (10 folds, 5 repeats), optimizing the SVM's hyperparamters using grid search. Results: The test showed a good reproducibility. With a mean percentage of 74±0.98 SE and 66±1.17 SE, respectively, the physicians OSSA rating was significantly higher than the rating of the patients (p wilcoxon <0.001). Models predicting main diagnoses were constructed and estimated to perform with multi-class AUCs of 63.5% and 73.4% based on patient's and physician's OSSA, respectively. Conclusions: In this preliminary trial with low sample size the Popgen-OSSA showed a good reproducibility and allowed a correct allocation of the patient's clinical problem to involved organ system by SVM analysis with multi-class AUC of up to 73.4%. These data merit further investigation and development of the Popgen-OSSA on larger patient cohorts. (2) to compare results to a well-established laboratory reference method using patient samples.
Methods:
The Quantum Blue ® sCAL sandwich lateral flow immunoassay uses two highly specific monoclonal antibodies immobilized on the test membrane and on the gold label. 10μL of serum was diluted in 90μL of chase buffer, 60μL of this mixture was applied onto the lateral flow test cassette, which was incubated for 12 minutes at ambient temperature and then measured with the BÜHLMANN Quantum Blue ® Reader. Performance evaluation (sensitivity, linearity, high-dose hook effect, interferences) was carried out according to CLSI guidelines. A method comparison based on 178 serum samples from RA and PsA patients was performed against the BÜHLMANN sCAL (MRP8/14) reference ELISA. Results: The linearity study over the complete measuring range together with the observed limit of quantification (LoQ) of <0.5 μg/mL allowed a quantitative measurement in the clinically relevant range from 0.5 to 10.0 μg/mL calprotectin. No high dose hook effect was observed up to a concentration of 200 μg/mL. Moreover, no interferences were detected with triglycerides (37mmol/L), conjugated bilirubin (342μmol/L), unconjugated bilirubin (342μmol/L), and hemoglobin (200mg/dL). The Quantum Blue ® sCAL lateral flow assay showed an excellent linear correlation (r=0.94, slope=1.05) to the BÜHLMANN sCAL (MRP8/14) reference ELISA. There was a negligible bias of -3.1% by Bland-Altman difference plot between the sCAL lateral flow assay and ELISA. Conclusions: Rapid quantification of serum calprotectin using the Quantum Blue ® sCAL assay represents a fast and reliable method for the determination of inflammation and the disease activity of a patient with inflammatory arthritis at the point of care. This rapid test shows excellent agreement to a corresponding laboratory reference method. Background: Axial spondyloarthritis (axSpA) mainly affects the working-age subject and can have a moderate (short-term sick leave) or significant (long-term sick leave, disability status, unemployment) work impact. Objectives: To evaluate the value of a simple and short (2 minutes) questionnaire, the AS-Work instability scale (AS-WIS) to predict the work impact of axSpA after 1-2 years. Methods: Longitudinal study in 3 centers in Paris, France. Patients with axSpA according to the rheumatologist and the ASAS criteria were included. Patients were asked twice (1 to 2 year interval) to answer questionnaires evaluating: disease activity, demographic characteristics, impact on work (short-term and long-term sick leave, disability, unemployment), and the ASWIS questionnaire (1): a 20 item, simple screening tool for Work Instability (the consequences of a mis-match between an individual's functional ability and their work tasks). The risk of disability is assessed as low if the score is <11, medium between 11-18 and high>18.
Only patients who answered both questionnaires were included for analyses. Statistical analyses included descriptive analyses and univariate/ multivariate analyses to search for baseline factors of work impact at 1-2 years (including a medium/high ASWIS score, gender, age, schooling level, BASDAI, BASFI). Results: Among the 188 patients who answered the first questionnaire, 144 were currently working and were asked to answer the second questionnaire. A total of 101 patients answered both questionnaires. Mean age at inclusion was 45 (SD 9) years, 52% were male, disease duration was 14 (SD 8) years and 62% had an education level equivalent to more than high school. The BASDAI and the BASFI were respectively 34 (SD 21) and 23 (SD 23). At baseline, median ASWIS was 10, a low-risk score was found in 55 patients (54%), and a medium/high risk score in 46 (46%). 1 -2 years later, 37 patients (36%) had work impact: 25 patients (25%) a short-term sick leave, and 12 patients (12%) a significant work impact (long-term disability or unemployment due to Ax-SpA). Among patients with a low ASWIS score at baseline (n=55), only 13 (24%) had a work impact (including only 2 with a significant impact). Among patients with a medium/high ASWIS score (n=46), 24 (52%) had a work impact (including 10 patients of a significant impact). In univariate analysis, baseline factors associated with work impact (moderate or significant) were a medium/high ASWIS score, a high BASFI and a shorter disease duration. In multivariate analysis, medium/high ASWIS (odds ratio, OR 2.71 (1.04-7.22)) and a lower disease duration (0.94 (0.89-0.99)) were independent predictive factors of work impact.
Conclusions:
In patients with axSpA, a medium/high ASWIS score was followed by a work impact in 50% of cases within 2 years in this well-controlled population. This short questionnaire can be helpful to screen for future difficulties at work, whatever the stage of disease. 
